T2 - Translation to Patients - Part II (6:50)

Loading...

來自 University of Rochester 的課程

Introduction to Translational Science

22 個評分

University of Rochester

Introduction to Translational Science

22 個評分

Translational science seeks to speed up the process of moving research discoveries from the laboratory into healthcare practices. Numerous scientific and organizational roadblocks can act as obstacles along the path of translation and ultimately hinder the speed of progress in medical research. The National Center for Advancing Translational Sciences (NCATS) was established by the National Institutes of Health (NIH) to transform and accelerate the translational research process, with the intended result of getting treatments to more patients faster. The field of Translational Science aims to bridge these gaps by: Developing new approaches, technologies, resources and models Demonstrating the usefulness of new approaches, technologies, resources and models Disseminating the resulting data, analyses, and methodologies to the broad scientific community Introduction to Translational Science is an introductory course that provides students with a broad understanding of translational science, the types of research that are conducted under the translational science umbrella, and how this research impacts the public at large.The course will compare and contrast current impediments to clinical research with the potential of translational science and will include selected case studies from the University of Rochester.

從本節課中

T2 - Translation to Patients and T3 - Translation to Practice

The third lesson in Introduction to Translational Science provides an introduction to T2 research, which is research that translates findings from T1 research (humans) to patients. T2 research is often conducted through Phase III clinical trials, observational studies, evidence synthesis, and clinical guidelines development. The fourth lesson in Introduction to Translational Science provides an introduction to T3 research, which is research that translates findings from T2 research (patients) to actual clinical practices. T3 research is often conducted through Phase IV clinical trials, health services research, and clinical outcomes research.

T2 - Translation to Patients - Introduction (9:18)9:18

T2 - Translation to Patients - Part I (7:34)7:33

T2 - Translation to Patients - Part II (6:50)6:50

T2 - Translation to Patients - Part III (6:50)6:50

T2 - Translation to Patients - Part IV (9:55)9:55

與講師見面

Martin S. Zand, MD, PhD
Professor of Medicine – Nephrology
School of Medicine

[MUSIC]

Many of our efforts to date, patients have instrumental, and

not only participating in the study for which we're very thankful, but

in the actual design and conduct of the study.

So we had, for our telemedicine study,

we had a patient who was a member of our steering committee.

Who helped in the design, conduct, and interpretation of the results.

We had a patient advisor group that gave us invaluable guidance on

everything from our website.

To helping recruit participants that participate in this study.

In our smartphone application, we had a group of dedicated volunteers,

who were willing to test out the smartphone application, and

give us feedback and suggestions.

And importantly, the study itself,

we enabled people to give us suggestions on how to improve the app.

And we received over 20,000 suggestions on how to improve the app.

Many of which were incorporated in subsequent versions of it.

We're trying to identify, what are the needs of patients and

provide them the means for them to articulate their own needs, and

their own values, and their own preferences.

And we think and hope that some of the tools that we're developing,

whether that's receiving care in their homes on their terms.

Or being able to participate in research on their phones, on their terms,

are ways for them to do that.

I was very fortunate when I was here at the University of Rochester.

I think I was a fellow or

maybe a junior faculty member to receive a KL2 Development Award.

That let me work with outstanding people including Dr. Bob Holloway, Dr.

Ira Schosin, Dr. Karl Kepperts, and developing my early research interests.

Which were honestly ill-formed, not well formed.

And over that time it let me explore new areas of research,

including some new things like telemedicine.

Smartphones weren't quite on the radar screen 10 years ago.

The idea that you could use a smartphone

to conduct a clinical research wasn't quite there, but Town Medicine was.

As was, you know, trying to better understand how we can more effectively and

efficiently develop new drugs for neuro degenerative conditions like

Parkinson's Disease and Huntington's Disease I think,

three or five years from now, we're going to view telemedicine as blase.

And the idea that patients should be able to receive care on their home

seems self-evident.

And we'll say, what the heck was the big deal at the time?

And we'll also think increasingly recognized that we shouldn't be asking

research participants who have oftentimes very disabling conditions.

And have overburdened caregivers to come to

us to participate in research studies on our terms.

That we should just like we are doing for care, enable research participants

to participate in clinical trials on their terms.

We should bring the trials to them, rather than asking patients who are burdened by

diseases to come see us on ours.

When Apple released this research kit in 2014, as an Open Source platform for

developing research studies, it was quite new.

So, the smartphone was only about eight years old now.

And the idea of using a smart phone to conduct clinical research was

very much a foreign idea.

And they were working with academics, which was relatively new to them.

And they weren't certain that academics could keep their mouths quiet,

and not leak out the news of their substantial new effort.

And so, they made the announcement in the morning about ResearchKit, and

later in the day, we got news, they were able to track data in real time.

That over 2,000 people had signed up to participate in the mPower app.

2,000 people would represent more than the largest number of research

participants in the clinical trial ever in Parkinson's Disease.

So this was clearly a sign that they had tapped into something, and unmet need.

A thirst that individuals wanted to participate in reasearch studies, and

to do so on their terms.

So, I think opening a new chapter on the way we conduct clinical research.

A chapter that will likely not close soon, and has many more pages to be written.

We know that people want to participate in clinical trials.

That people with cancer want to advance research, they want to advance knowledge.

But only like 2 or 3% of individuals with cancer for example,

participate in clinical trials.

Now, we enable you know 90 plus percent of the population

that has a smartphone to participate in research studies on their terms,

without them ever having to come in to a research study.

It's not quite a clinical trial, but it's a research study.

We think, five applications for initially release, one for asthma, one for breast

cancer, one for cardiovascular disease, diabetes, and Parkinson's disease.

There are probably hundreds of applications now,

everything from autism to LGBTQ community,

to prostate cancer, to congestive heart failure.

So, this just opens a new way of engaging people in research studies.

And I think, it's only a matter of time before these new ways of conducting

research studies will translate into new ways of conducting clinical trials.

It was pretty cool, that you're there, and

you're interacting with now the Chief Operating Officer of Apple.

And for the whole community, and

people who are new to clinical research to find out that they've tapped

into something that was a need that had been not well expressed.

And a means by which people could engage in research in new ways.

It was exciting for all of us.

Well I think, we're now at the point where we can use these smartphones to

facilitate diagnosis of Parkinson's disease.

So can you press a button on your phone, do a series of tasks?

You know, a voice recording saying doing a tapping task, and walking 20 feet.

And get the sense of whether you're at high risk for having Parkinson's disease,

or at low risk for Parkinson's disease.

In United States, it may not seem like a very big deal, but in China,

there's over two million people with Parkinson's disease, and

only 50 to a hundred Parkinson's disease specialist.

So can you a press the button, and

determine whether you're likely to have Parkinson's disease?

And then, if you find out you're high risk for having Parkinson's disease.

Can you press that exact same button, or the button next to it, and

be connected to a connection?

We think that we carry these tools around with us,

then 90% of the world's population over age of six will have by 2020.

And that indeed, we'll be able to press buttons,

and help to determine whether we have a given condition.

And second, and perhaps more importantly, be able to press a button to help be

connected to care, which with the history of human kind has never been possible.

[MUSIC]

探索我們的目錄

免費加入並獲得個性化推薦、更新和優惠。

Coursera 致力於普及全世界最好的教育，它與全球一流大學和機構合作提供在線課程。

© 2019 Coursera Inc. 保留所有權利。

通過 App Store 下載

通過 Google Play 獲取